Daiichi Sankyo
Our long history of scientific leadership includes the discoveries of vitamin B1 and troglitazone, and the first isolation of epinephrine – better known as adrenaline. Our research has led to new classes of pharmaceuticals for hypertension, oncology and more, such as the discovery of the statin class of lipid-lowering agents and the development of the first glitazone, which revolutionized long-term control of type 2 diabetes.
Today, innovation remains at the center of everything we do. We build on our legacy through ongoing research to create world-class medicines, pairing existing ideas with new ones, as we pursue our highest goal: to improve quality of life for patients around the globe.
We know that our success is linked to the success of our employees. Each member of our organization contributes to our pursuit of our goals and our company vision. We hold ourselves to high standards in a competitive industry – but our culture sets us apart. Daiichi Sankyo is proud to foster an environment of collaboration and ideas
Our comprehensive product portfolio offers a wide range of treatments for patients in a number of disease categories including hypertension, heart disease, diabetes and hyperlipidemia/ atherosclerosis. Our pipeline of compounds focuses on these product categories and explores oncology therapies.
Our commitment to improving lives is the core of our business, but it doesn’t end with our products and pipeline. We are proud members of the communities in which we live and work, as individuals and as an organization. Through corporate philanthropy, community service, patient assistance and more, we’re moving forward by giving back.
Pharmaceutical innovation and therapeutic advances have had a dramatic impact on the lives of millions of people throughout the world. Innovation is our passion, as well as a fundamental requirement in our ongoing pursuit to create innovative, world-class medicines
We are distinguished by integrity. We strive not only to do things right, but to do the right things to improve the health and well-being of patients.
Accountability is the cornerstone of our culture. It is at the intersection of research and patient need that we find our greatest challenges and our most extraordinary opportunities. We demonstrate our compassion for people by honoring our commitments to all those who depend on us to provide innovative therapies to patients.
-
“The culture here at Daiichi Sankyo is unique because we’re all empowered and encouraged to find and hone our individual crafts. Yet we know we’re better when we combine them and work together as one team. Whether you’ve worked at Daiichi Sankyo for a decade or a day my hope is everyone sees themselves within all that we do for people impacted by cancer.”
Dan Switzer, Head of US Oncology Business Division -
“It’s not just a tagline. ‘Compassion for patients’ is a genuine part of who we are. While I may play a more active role in patient advocacy, the passion and dedication to making a positive impact can be felt throughout the entire organization. I love that we are mission-driven and aligned on patient centricity.”
Clarissa Stamler, Director, GMA Patient Advocacy, Oncology
